Synthetic pentadecapeptide
Also: Body Protection Compound 157 · Pentadecapeptide BPC 157
Short answer
BPC-157 is a Regulatory status: Compounding under review. Nominated for the 503A bulk drug list; advisory votes and reviews are not approval.
Evidence ladder — counts appear as reviewed claims are published
Weakest to strongest. Hover a level to see what it means.
In editorial review
Receptor interactions, pathways and proposed mechanisms, with the evidence level for each. Each statement is stored as a cited claim and must pass reviewer approval before it appears here — we publish nothing unsourced.
How claims are reviewed →In editorial review
Human, animal and laboratory studies, summarised in our own words with population, design, findings and limitations. Each statement is stored as a cited claim and must pass reviewer approval before it appears here — we publish nothing unsourced.
How claims are reviewed →In editorial review
Documented adverse effects, contraindications, interactions and what remains unknown. Each statement is stored as a cited claim and must pass reviewer approval before it appears here — we publish nothing unsourced.
How claims are reviewed →Dated, sourced events. Advisory committee votes and 503A bulks-list actions are distinct from drug approval under section 505 of the FD&C Act.
Compounding list
FDA published a notice scheduling a Pharmacy Compounding Advisory Committee meeting and said it would remove twelve peptides from Category 2 of its interim 503A bulks list after nominators withdrew their nominations.
What this doesn't mean: Removal from Category 2 does not make a substance eligible for compounding, and it is not FDA approval.
Advisory vote
The advisory committee voted 8–6 (1 abstention) on BPC-157, KPV and TB-500, and 7–5 (2 abstentions) on MOTS-c, recommending each be added to the 503A Bulk Drugs List.
What this doesn't mean: Advisory votes are recommendations. FDA must complete rulemaking before any of these can be lawfully compounded, and inclusion on the bulks list is not drug approval.
In editorial review
Registered studies synced from ClinicalTrials.gov: phase, status, enrollment and whether results have been posted. Each statement is stored as a cited claim and must pass reviewer approval before it appears here — we publish nothing unsourced.
How claims are reviewed →In editorial review
Every source cited on this page, with links to PubMed, ClinicalTrials.gov and FDA records. Each statement is stored as a cited claim and must pass reviewer approval before it appears here — we publish nothing unsourced.
How claims are reviewed →